France's Erytech Closer To Realizing Market Ambitions With Eryaspase US Filing
Positive FDA Feedback For Leukemia Submission
It has taken almost two decades but it looks as though Erytech could get approval for eryaspase in the US in two indications next year – acute lymphoblastic leukemia and pancreatic cancer.
